Companies

ABBOTT LABORATORIES

ABT · CIK 0000001800 · operating

$116.35+0.08%Last updated Feb 27, 10:04 PM

Key Statistics

Valuation

Market Cap$202.50B
P/E31.28
Fwd P/E18.63
PEG
P/S4.57
P/B3.88
EV/EBITDA17.29
EV/Rev4.69

Profitability

Gross Margin
Op. Margin18.17%
Net Margin14.72%
ROE12.51%
ROA7.52%
FCF Margin16.68%

Financial Health

Current Ratio1.58
Debt/Equity
Free Cash Flow$7.39B
Div. Yield2.17%

Growth & Other

Revenue Growth5.67%
EPS Growth-51.31%
Beta0.75
52W High$141.23
52W Low$105.27

About ABBOTT LABORATORIES

Abbott Laboratories discovers, develops, manufactures, and sells health care products through four operating segments. The Established Pharmaceutical Products segment comprises generic medications for conditions including hypertension, hypothyroidism, dyslipidemia, pain, and inflammation. The Diagnostic Products segment includes laboratory systems for immunoassay and clinical chemistry testing, molecular diagnostics platforms, point-of-care testing systems, and rapid diagnostics for infectious diseases including COVID-19 and influenza. The Nutritional Products segment manufactures pediatric and adult nutritional products and infant formula. The Medical Devices segment produces cardiovascular devices for rhythm management and structural heart treatment, diabetes care systems with glucose monitoring capabilities, and neuromodulation devices for chronic pain and movement disorder management.

The company operates globally from its headquarters in Abbott Park, Illinois, with approximately 115,000 full-time employees worldwide. Abbott was founded in 1888 and is incorporated in Illinois. The company maintains a presence across developed and emerging markets, serving healthcare providers, patients, and consumers through multiple distribution channels spanning pharmaceutical, diagnostic, nutritional, and medical device categories.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2025$3.72$3.73-51.3%
2024$7.64$7.67+134.4%
2023$3.26$3.28-16.6%
2022$3.91$3.94-0.8%
2021$3.94$3.97+57.6%
2020$2.50$2.52+323.7%
2019$0.59$0.59+59.5%
2018$0.37$0.37+177.1%
2017$-0.48$-0.48-190.6%
2016$0.53$0.54+3.9%
2015$0.51$0.51-13.6%
2014$0.59$0.59+59.5%
2013$0.37$0.38-43.9%
2012$0.66$0.66-35.3%
2011$1.02$1.03+10.9%
2010$0.92$0.93-75.1%
2009$3.69$3.71

Annual Reports (10-K) · 8 filings

Report DateFiledAccession Number
2025-12-312026-02-200001628280-26-010185SEC ↗
2024-12-312025-02-210001628280-25-007110SEC ↗
2023-12-312024-02-160001628280-24-005348SEC ↗
2022-12-312023-02-170001628280-23-004026SEC ↗
2021-12-312022-02-180001104659-22-025141SEC ↗
2020-12-312021-02-190001104659-21-025751SEC ↗
2019-12-312020-02-210001104659-20-023904SEC ↗
2018-12-312019-02-220001047469-19-000624SEC ↗